Scotiabank Initiates Coverage On Tempest Therapeutics with Sector Outperform Rating, Announces Price Target of $13
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst George Farmer initiates coverage on Tempest Therapeutics (NASDAQ:TPST) with a Sector Outperform rating and a price target of $13.

March 13, 2024 | 9:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scotiabank initiated coverage on Tempest Therapeutics with a Sector Outperform rating and set a price target of $13.
The initiation of coverage by Scotiabank with a Sector Outperform rating and a price target significantly above the current trading price is likely to be viewed positively by investors. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100